40.3: Psoriatic Drugs
By the end of this section, you should be able to:
- 40.3.1 Identify the characteristics of drugs used to treat psoriasis.
- 40.3.2 Explain the indications, actions, adverse reactions, and interactions of drugs used to treat psoriasis.
- 40.3.3 Describe nursing implications of drugs used to treat psoriasis.
- 40.3.4 Explain the client education related to drugs used to treat psoriasis.
Psoriasis is a T-lymphocyte–mediated autoimmune disease that mainly affects the skin. In many cases, however, it also affects the eyes, joints, and nails. Plaque psoriasis is the subtype of psoriasis that affects the skin. In this condition, skin cells mature faster than normal, resulting in white-silvery plaques on body surfaces with red, erythematous lesions below (see Figure 40.4). The head and scalp, eyes, elbows, knees, and back are primarily affected by these plaques. Plaque psoriasis may range from very mild with few lesions to severe, with large areas of disfiguring plaques. Treatment of psoriasis involves combination systemic and topical therapies used to decrease inflammation, exfoliate skin plaques, and decrease the mitotic rate and maturation of skin cells.
Adverse Effects and Contraindications
Systemic psoriatic drugs that are classified as retinoids may cause systemic effects such as hypersensitivities, hypervitaminosis A syndrome, myocardial infarction, stroke, thromboembolism, neuropathy, yeast infections, capillary leak syndrome, exfoliative dermatitis, and skin fragility. These drugs are contraindicated in clients with pre-existing cardiac, renal, and hepatic conditions. As mentioned, methoxsalen may cause severe burning of the skin when clients are exposed to UV light. Use in clients receiving UV treatments and who are exposed to the sun may be contraindicated or require dose reductions. Retinoids, such as acitretin, are contraindicated for those who could become pregnant, are pregnant, or are breastfeeding.
Table 40.6 is a drug prototype table for systemic psoriatic drugs featuring acitretin. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.
|
Drug Class
Retinoid Mechanism of Action Assists in regulating mitotic rate of skin cells |
Drug Dosage
25–50 mg orally once daily with main meal. |
|
Indications
Psoriasis Therapeutic Effects Decreases psoriatic plaque formation |
Drug Interactions
Tetracycline drugs Methotrexate Food Interactions No significant interactions |
|
Adverse Reactions
Hypersensitivity Hypervitaminosis A syndrome Myocardial infarction Stroke Thromboembolism Neuropathy Yeast infections Capillary leak syndrome Exfoliative dermatitis Skin fragility |
Contraindications
Hypersensitivity Liver or kidney disease Hyperlipidemia Pregnancy |
Nursing Implications
The nurse should do the following for clients who are taking systemic psoriatic drugs:
- Ensure that clients have met required screening to receive prescriptions for systemic psoriatic medications.
- Assess and thoroughly document baseline skin condition.
- Assess and monitor the client for adverse effects, drug and food interactions, and contraindications.
- Evaluate and document the client’s response to current treatment and overall improvement of skin condition.
- Assess the psychosocial impact of psoriasis on individual clients.
- Provide client teaching regarding the drug and when to call the health care provider. See the end of this section for client teaching guidelines.
Topical Psoriatic Drugs
Topical therapies for treating psoriasis decrease the mitotic rate and differentiation of skin cells in the epidermis. Calcipotriene, a vitamin D analog, blocks vitamin D receptors in the skin to decrease skin cell production. Clobetasol, a topical steroid, reduces inflammation associated with psoriasis. This medication is only used in clients over 12 years of age. Application of clobetasol is limited to those areas that are not on the face, genitals, and axillae. It is important to remember that clients may experience systemic steroidal effects. For this reason, clobetasol should be limited to use for 2 weeks or less.
Coal tar is another topical medication that treats the itching, redness, and scaliness associated with psoriasis. Coal tar, along with anthralin, should not be applied to the skin surrounding the psoriatic lesions. Petrolatum or zinc oxide ointments may be used to coat the normal surrounding tissues before medication administration to protect the normal tissue. Tazarotene, as with treatment for acne, is thought to assist with reducing discolorations in the skin and may also play a role in reduction of scarring from psoriatic lesions.
Table 40.7 lists common topical psoriatic drugs and typical routes and dosing for adult and pediatric clients .
| Drug | Routes and Dosage Ranges |
|---|---|
|
Clobetasol
( Dermovate , ClobaDerm , Etrivex ) |
Adults and children ≥12 years: Apply aerosol foam (0.05%) topically in a thin layer twice daily for 2 weeks. |
| Calcipotriene | Adults: Apply ointment (0.005%) topically, rubbing gently on lesions 1–2 times daily. |
|
Coal tar lotion
( Cutar ) Coal tar shampoo ( Psoriderm , Exorex , Polyderm ) |
Adults:
Lotion (8%): Apply to affected areas 1–4 times daily. Shampoo (5%): Shake well, apply to wet hair, gently massage into hair and scalp to work up a lather. Rinse thoroughly and repeat. Use at least twice a week or as directed. |
|
Tazarotene
( Tazorac ) |
Adults:
Apply a thin layer topically, once daily in the evening.
Children: Safety and efficacy have not been established in clients under the age of 18. |
Adverse Effects and Contraindications
Topical treatments for psoriasis are contraindicated for areas of open skin, mucous membranes, genitals, and the face. Adverse effects may be related to improper use of these medications. Applying too much or too often may cause excessive drying and irritation of the skin. Redness, flaking, or broken areas may also develop with improper use (DailyMed, Tazarotene , 2023).
Table 40.8 is a drug prototype table for systemic psoriatic drugs featuring coal tar. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.
|
Drug Class
Psoriatic Mechanism of Action Assists in treating redness, scaling, and itching of psoriatic lesions |
Drug Dosage
Adults: Lotion (8%): Apply to affected areas 1–4 times daily. Shampoo (5%): Shake well, apply to wet hair, gently massage into hair and scalp to work up a lather. Rinse thoroughly and repeat. Use at least twice a week or as directed. |
|
Indications
Psoriasis Therapeutic Effects Decreases itching, redness, and scaling of psoriatic plaques |
Drug Interactions
No significant interactions Food Interactions No significant interactions |
|
Adverse Reactions
Rash Skin irritation |
Contraindications
Hypersensitivity UV light/sun exposure |
Nursing Implications
The nurse should do the following for clients who are taking topical psoriatic drugs:
- Assess and thoroughly document baseline skin condition.
- Observe for hypersensitivity reactions or worsening of symptoms.
- Assess for prolonged use or excessive application by clients.
- Evaluate and document the client’s response to current treatment and overall improvement of skin condition.
- Assess the psychosocial impact of psoriasis on individual clients.
- Provide client teaching regarding the drug and when to call the health care provider. See the end of this section for client teaching guidelines.
Biologic Psoriatic Drugs
Biologic response modifiers and monoclonal antibodies are used in the treatment of psoriasis and other autoimmune diseases to reduce inflammation. Etanercept and infliximab decrease inflammation in psoriasis by inhibiting the action of tumor necrosis factor (TNF), substances within the body that stimulate immune responses and produce inflammatory effects. Adalimumab and ustekinumab are monoclonal antibodies that help to decrease inflammation as well but do so by affecting T-cell response through the inhibition of interleukin-12 and interleukin-23.
Table 40.9 lists common biologic psoriatic drugs and typical routes and dosing for adult and pediatric clients .
| Drug | Routes and Dosage Ranges |
|---|---|
|
Etanercept
( Enbrel ) |
Adults and children ≥63 kg:
50 mg subcutaneous injection twice weekly for 3 months, then weekly for maintenance.
Children <63 kg: 0.8 mg/kg subcutaneous injection weekly. |
|
Infliximab
( Remicade ) |
Adults:
5 mg/kg intravenous (IV) infusion on weeks 0, 2, and 6, then every 8 weeks thereafter.
Children: Safety and efficacy for use in psoriasis have not been established in clients under the age of 17. |
|
Adalimumab
( Humira ) |
Adults:
Initial dose: 80 mg subcutaneously, then 40 mg every other week.
Children: Safety and efficacy for use in psoriasis have not been established in clients under the age of 17. |
|
Ustekinumab
( Stellara ) |
Adults and children >100 kg:
90 mg subcutaneously initially, then 4 weeks later, then 90 mg every 12 weeks.
Adults and children ≤100 kg: 45 mg subcutaneously initially, then 4 weeks later, then 45 mg every 12 weeks. Children <60 kg: 0.75 mg/kg subcutaneously. Follow the adult administration timeframe but use weight-based guidelines to administer the same dose at each scheduled interval. |
Adverse Effects and Contraindications
The use of biologic drugs in psoriasis is associated with hypersensitivity reactions to the proteins that comprise these drugs. Because these drugs suppress the immune system to reduce inflammation, they can increase a client’s risk for serious, often life-threatening infections. Additionally, the immunosuppressive effects can cause secondary malignancies to develop, especially lymphomas. These medications are contraindicated for those clients who have infections, immunosuppressive conditions, or who may be taking other immunosuppressive treatments.
Table 40.10 is a drug prototype table for biologic psoriatic drugs featuring adalimumab. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.
|
Drug Class
TNF blocker, monoclonal antibody Mechanism of Action Binds to TNF to block action of tumor necrosis factor–mediated inflammation Decreases scaling of skin |
Drug Dosing
Adults: Initial dose: 80 mg subcutaneously, then 40 mg every other week. Children: Safety and efficacy for use in psoriasis have not been established in clients under the age of 17. |
|
Indications
Plaque psoriasis Therapeutic Effects Systemically reduces inflammation associated with plaque psoriasis and other autoimmune diseases |
Drug Interactions
Cytochrome P450 substrates Anticoagulants Cyclosporine Theophylline Food Interactions No significant interactions |
|
Adverse Reactions
Bacterial infections Yeast infections Neutropenia Anaphylaxis Secondary malignancies Heart failure |
Contraindications
Hypersensitivity Caution: Clients at higher risk of infection |
Nursing Implications
The nurse should do the following for clients who are taking biologic psoriatic drugs:
- Conduct vigilant assessments for baseline, response to treatment, adverse effects, infection, and secondary malignancies.
- Evaluate blood urea nitrogen (BUN), creatinine, and glomerular filtration rate for renal function; review liver function tests for hepatotoxicity.
- Ensure client received tuberculosis screening before initiation of therapy.
- Observe for hypersensitivity reactions during and after administration.
- Emphasize the importance of compliance with instructions and follow up with clients when necessary.
- Assess and monitor the client for adverse effects, drug and food interactions, and contraindications.
- Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.
Client Teaching Guidelines
The client taking a systemic psoriatic medication should:
- Take prescribed medications exactly as directed.
- Report side effects such as skin redness, excessive dryness, or peeling to the primary provider.
- Report temperature above 100.4°F, chills, productive cough, and symptoms of urinary tract or other infections immediately.
- Avoid crowds or others who are sick or who have received live vaccines in the last 3 months.
- Use birth control methods as instructed and avoid pregnancy.
- Refrain from breastfeeding.
- Avoid UV light exposure (methoxsalen).
- Follow up with appointments as instructed.
The client taking a topical psoriatic medication should:
- Take prescribed medications exactly as directed.
- Report side effects such as skin redness, excessive dryness, or peeling to the primary provider.
- Cleanse skin thoroughly before applying medication.
- Apply only a thin layer of medications to the affected areas only.
- Avoid contact with eyes and mucous membranes.
- Wash hands well before and after application.
The client taking a topical psoriatic medication should not :
- Cover the medication with occlusive dressings.
- Get the medication on clothing or other fabrics because it causes staining.
The client taking a biologic psoriatic medication should:
- Take medications exactly as instructed.
- Follow up with appointments.
- Report temperatures above 100.4°F to their health care provider.
- Contact the primary provider for productive cough, symptoms of urinary tract infection, yeast infection, or other unusual symptoms.
- Continue lifelong follow-ups for monitoring for secondary malignancies.
- Avoid crowds and other exposures to people with infections.
- Avoid contact with those who have had live virus vaccinations within 3 months.
FDA Black Box Warning
Psoriatic Medications
Acitretin can cause embryo-fetal loss and malformations when administered to a pregnant client.
Methoxsalen can cause severe photosensitivity, ocular damage, skin aging, and skin cancers.
Infliximab, adalimumab , and ustekinumab can increase the risk of serious infections and the development of secondary malignancies.